Anthelmintic Flubendazole and Its Potential Use in Anticancer Therapy
Language English Country Czech Republic Media print-electronic
Document type Journal Article, Review
PubMed
28399389
DOI
10.14712/18059694.2017.44
PII: 18059694.2017.44
Knihovny.cz E-resources
- Keywords
- anti-cancer treatment, benzimidazole carbamate, flubendazole, melanoma, microtubules, mitotic catastrophe,
- MeSH
- Leukemia drug therapy MeSH
- Humans MeSH
- Mebendazole analogs & derivatives therapeutic use MeSH
- Microtubules metabolism MeSH
- Multiple Myeloma drug therapy MeSH
- Cellular Senescence drug effects MeSH
- Tubulin metabolism MeSH
- Cell Survival MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- flubendazole MeSH Browser
- Mebendazole MeSH
- Tubulin MeSH
Flubendazole is a widely used anthelmintic drug belonging to benzimidazole group. The molecular mechanism of action of flubendazole is based on its specific binding to tubulin, which results in disruption of microtubule structure and function, and in the interference with the microtubule-mediated transport of secretory vesicles in absorptive tissues of helminths. The microtubule-disrupting properties of benzimidazole derivatives raised recently interest in these compounds as possible anti-cancer agents. In this minireview flubendazole effects towards selected human malignant cells including myeloma, leukemia, neuroblastoma, breast cancer, colorectal cancer and melanoma are discussed along with basic data on its pharmacokinetics, metabolism and toxicity.
References provided by Crossref.org
